U.S. Markets closed

Novartis AG (NVS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
83.18-1.19 (-1.41%)
At close: 4:02PM EDT

83.11 -0.07 (-0.08%)
After hours: 7:11PM EDT

People also watch
GSKSNYAZNLLYABT
Full screen
Previous Close84.37
Open84.04
Bid0.00 x 0
Ask0.00 x 0
Day's Range83.15 - 84.24
52 Week Range66.93 - 86.90
Volume920,180
Avg. Volume1,958,310
Market Cap194.77B
Beta0.70
PE Ratio (TTM)31.27
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.72 (3.22%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Cramer's lightning round: I don't want to recommend any oil stocks right now
    CNBC4 hours ago

    Cramer's lightning round: I don't want to recommend any oil stocks right now

    Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name.

  • Ophthotech's Fovista Combo Regimen Disappoints in Phase III
    Zacksyesterday

    Ophthotech's Fovista Combo Regimen Disappoints in Phase III

    Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.

  • Zacks Small Cap Researchyesterday

    CYRX: Raising Price Target on CAR-T Opportunity

    Cryoport (CYRX) reported Q2 2017 financial results.  Results continue to impress as revenue set another new high, extending that streak to 11 straight quarters.  Consistent increases in the number of clinical trials that the company supports remains the major catalyst to the topline growth.  That metric (i.e. Q2 revenue, at $2.9M, was up 52% yoy and inline with our $2.9M estimate.  It is also a new record and up almost 8% sequentially from Q1 (the prior best).  This is the fifth consecutive quarter in which revenue came in slightly better and operating loss much better than our respective estimates.  The $60k revenue difference in Q2 compared to our estimate relates to $36k beat ($2.22M A vs. $2.19M) in biopharma and $25k ($426k A vs. $401k E) beat in reproductive medicine, partially offset by $20k miss ($263k A vs. $283k E) in animal health.